ASMBS: Bariatric Surgery Improves Heart Disease Markers

Share this content:
ASMBS: Bariatric Surgery Improves Heart Disease Markers
ASMBS: Bariatric Surgery Improves Heart Disease Markers

(HealthDay News) – In addition to weight loss, over the long term, gastric bypass surgery improves biochemical cardiac risk factors, including an 80% drop in C-reactive protein, according to a study presented at the annual meeting of the American Society for Metabolic and Bariatric Surgery, held from June 17 to 22 in San Diego.

Nayna Lodhia, from Stanford University in California, and colleagues analyzed changes to 11 cardiac risk factors in 182 patients (mean body mass index, 47kg/m²; average weight, 286 pounds) who underwent gastric bypass surgery. Statins were discontinued after surgery.

By 7 years after surgery, the researchers found that the average body mass index was reduced to 34kg/m² and the average weight fell to 205 pounds. Patients had improvements in all risk factors, including a 40% increase in high-density lipoproteins, a 66% decrease in fasting insulin levels, a 55% reduction in triglycerides, and an 80% decrease in C-reactive protein.

"An 80% reduction in the C-reactive protein level is an astounding drop," a coauthor said in a statement. "This is significantly better than what the best medical therapy has been shown to achieve and underscores the inflammatory nature of obesity, which can be reversed with surgical weight loss."

Abstract No. PL-114
More Information

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs